Free Trial
NASDAQ:RAPT

RAPT Therapeutics Q3 2024 Earnings Report

RAPT Therapeutics logo
$0.97 +0.05 (+5.64%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+1.26%)
As of 05/2/2025 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

RAPT Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

RAPT Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

RAPT Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

RAPT Therapeutics Earnings Headlines

Rapt Therapeutics appoints Jessica Savage as VP, clinical development
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More RAPT Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RAPT Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RAPT Therapeutics and other key companies, straight to your email.

About RAPT Therapeutics

RAPT Therapeutics (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

View RAPT Therapeutics Profile

More Earnings Resources from MarketBeat